Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 3, 2001, Pages 371-377

  Ierardi, E ^a   Principi, M ^a   Francavilla, R ^a   Pisani, A ^a   Rendina, M ^a   Ingrosso, M ^a   Guglielmi, F W ^a   Panella, C ^b   Francavilla, A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; DEFLAZACORT; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISONE; STEROID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; ENTERITIS; FEMALE; FISTULA; HOSPITALIZATION; HUMAN; LONG TERM CARE; MALE; PARENTERAL NUTRITION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; QUALITY OF LIFE; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0035115453     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00938.x     Document Type: Article

References (32)

1. Cortisone in ulcerative colitis: Final report on a therapeutic trial
2. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
3. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine and methotrexate
4. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
5. Effect of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients
6. Tacrolimus (FK 506) treatment for primary sclerosing cholangitis: Result of an open-label preliminary trial
7. The course of inflammatory bowel disease under FK 506 immunosuppression after liver transplantation for primary sclerosing cholangitis
8. A critical review of cyclosporine therapy in inflammatory bowel disease
9. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease
10. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A
11. Preliminary report on the use of oral tacrolimus (FKSO6) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease
12. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK 506)
13. Multicenter comparisons of Tacrolimus (FK506) whole blood concentrations as measured by the Abbott IM, analyzer and enzyme immunoassay with methylene chloride extraction
14. A new measure of health status for clinical trials in inflammatory bowel diseases
15. Frequency of glucocorticoid resistance or dependency in Crohn's disease
16. Predicting outcome in severe ulcerative colitis
17. Pouchitis after ileal anal pouch anastomosis: A pouchitis disease activity index
18. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: Time for a reappraisal?
19. Intravenous cyclosprin in attacks of ulcerative colitis
20. European trial of cyclosporine in chronic active Crohn's disease: A 12 month study
21. Low-dose cyclosporine for the treatment of Crohn's disease
22. Cyclosporin for the treatment of severe inflammatory bowel disease
23. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease
24. Intravenous cyclosporine in ulcerative colitis: A five-year experience
25. Risk factors for cyclosporine induced nephropathy in patients with auto-immune diseases
26. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations
27. Clinical course and management of inflammatory bowel disease after liver transplantation
28. Steroid-unresponsive acute attacks of inflammatory bowel disease: Immunomodulation by tacrolimus (FK506)
29. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum
30. Comparison of FK 506 and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile
31. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
32. Infectious complications in liver transplant recipients on Tacrolimus. Prospective analysis of 88 consecutive liver transplants